2003 NOV 4 - (NewsRx.com & NewsRx.net) -- Cangene Corporation (CNJ) announced that it has filed a Canadian New Drug Submission for Leucotropin, a protein known as GM-CSF.
The submission seeks approval from the Biologics and Genetic Therapies directorate for use of the drug in enhancing recovery of certain white blood cells in patients with Hodgkin disease and non-Hodgkin's Lymphoma following stem cell transplantation. Cangene developed Leucotropin with the Apotex Group, which plans to market the product in Canada.
"Leucotropin is the first of our recombinant biopharmaceutical products to be filed for regulatory approval and the filing is a significant step …
No comments:
Post a Comment